The Macrophage Colony Stimulating Factor 1 Receptor pipeline drugs market research report outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Macrophage Colony Stimulating Factor 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Central Nervous System, Immunology, and Respiratory which include the indications Solid Tumor, Colorectal Cancer, Amyotrophic Lateral Sclerosis, Neuroinflammation, Graft Versus Host Disease (GVHD), Autoimmune Disorders, Idiopathic Pulmonary Fibrosis, and Asthma. It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Macrophage Colony Stimulating Factor 1 Receptor pipeline targets constitutes close to 60 molecules. Out of which, approximately 57 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 6, 10, 8, 4, 15, and 9 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.

Macrophage Colony Stimulating Factor 1 Receptor overview

Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.

For a complete picture of Macrophage Colony Stimulating Factor 1 Receptor’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.